MA38569A1 - Composés pyrazino[1,2-a]indole, leur préparation et utilisation dans des médicaments - Google Patents

Composés pyrazino[1,2-a]indole, leur préparation et utilisation dans des médicaments

Info

Publication number
MA38569A1
MA38569A1 MA38569A MA38569A MA38569A1 MA 38569 A1 MA38569 A1 MA 38569A1 MA 38569 A MA38569 A MA 38569A MA 38569 A MA38569 A MA 38569A MA 38569 A1 MA38569 A1 MA 38569A1
Authority
MA
Morocco
Prior art keywords
pyrazino
medicaments
preparation
indole compounds
compounds
Prior art date
Application number
MA38569A
Other languages
English (en)
Inventor
Ramón Merce-Vidal
Fernández José Luis Díaz
Rosales Carmen Almansa
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA38569A1 publication Critical patent/MA38569A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention se réfère à des composés de formule générale (i) dans lesquels les variables prennent les diverses significations, des compositions pharmaceutiques les contenant et leur utilisation en médecine, en particulier dans la thérapie de la douleur.
MA38569A 2013-04-23 2014-04-22 Composés pyrazino[1,2-a]indole, leur préparation et utilisation dans des médicaments MA38569A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382145 2013-04-23
PCT/EP2014/058145 WO2014173901A1 (fr) 2013-04-23 2014-04-22 Composés pyrazino[1,2-a]indole, leur préparation et utilisation dans des médicaments

Publications (1)

Publication Number Publication Date
MA38569A1 true MA38569A1 (fr) 2017-03-31

Family

ID=48190444

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38569A MA38569A1 (fr) 2013-04-23 2014-04-22 Composés pyrazino[1,2-a]indole, leur préparation et utilisation dans des médicaments

Country Status (18)

Country Link
US (1) US9963453B2 (fr)
EP (1) EP2989104B1 (fr)
JP (1) JP6347830B2 (fr)
KR (1) KR20160003752A (fr)
CN (1) CN105263933B (fr)
AU (1) AU2014257578B2 (fr)
BR (1) BR112015026908A2 (fr)
CA (1) CA2909924A1 (fr)
ES (1) ES2754385T3 (fr)
MA (1) MA38569A1 (fr)
MX (1) MX2015014907A (fr)
PH (1) PH12015502420B1 (fr)
PT (1) PT2989104T (fr)
RU (1) RU2660417C2 (fr)
SG (1) SG11201508653QA (fr)
TN (1) TN2015000474A1 (fr)
WO (1) WO2014173901A1 (fr)
ZA (1) ZA201508613B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3697795T3 (fi) * 2017-10-17 2024-02-23 Acondicionamiento Tarrasense (R)-9-(2,5-difluorifenetyyli)-4-etyyli-2-metyyli-1-oksa-4,9-diatsaspiro[5.5]undekan-3-onin suoloja
CN118574832B (zh) * 2022-01-19 2026-05-29 无锡奕拓医药科技有限责任公司 三并环化合物、其制备、药物组合物及应用
WO2024105225A1 (fr) 2022-11-18 2024-05-23 Universitat De Barcelona Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317524A (en) 1965-02-04 1967-05-02 American Home Prod Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles
US4022778A (en) * 1971-11-05 1977-05-10 American Home Products Corporation 10-Aryl-1,2,3,4-tetrahydropyrazino(1,2-α)indole and derivatives thereof
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
WO1999059409A1 (fr) * 1998-05-21 1999-11-25 Matsumoto Rae R Composes et leur utilisation
WO2002010169A1 (fr) 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Derives de la piperazine
EP1487449A4 (fr) * 2001-12-21 2006-08-23 King Pharmaceuticals Res & Dev Derives de tyrosyle et leur utilisation comme modulateurs du recepteur p2x7
WO2008021463A2 (fr) 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Analogues de diaryl[a,d]cycloheptène à substitution amino, utilisés comme agonistes muscariniques et méthodes de traitement de troubles neuropsychiatriques
ITMI20040874A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
EP1829869A1 (fr) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Dérivés de 4,5,6,7-tétrahydrobenzo[b]thiophène et leur utilisaton comme ligands du récepteur sigma
EP1847542A1 (fr) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Dérivés de spiro[benzopyran] ou de spiro[benzofuran] comme antagonistes du récepteur sigma
EP1921073A1 (fr) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazoles en tant qu'inhibiteurs du récepteur sigma
EP1921071A1 (fr) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3-Triazoles en tant qu'inhibiteurs du récepteur sigma

Also Published As

Publication number Publication date
JP6347830B2 (ja) 2018-06-27
ES2754385T3 (es) 2020-04-17
ZA201508613B (en) 2017-08-30
MX2015014907A (es) 2016-03-07
WO2014173901A1 (fr) 2014-10-30
KR20160003752A (ko) 2016-01-11
JP2016516828A (ja) 2016-06-09
PT2989104T (pt) 2019-11-26
US20160075709A1 (en) 2016-03-17
US9963453B2 (en) 2018-05-08
BR112015026908A2 (pt) 2017-07-25
HK1221458A1 (en) 2017-06-02
EP2989104B1 (fr) 2019-08-21
AU2014257578A1 (en) 2015-11-12
PH12015502420A1 (en) 2016-02-22
PH12015502420B1 (en) 2018-09-26
SG11201508653QA (en) 2015-11-27
AU2014257578B2 (en) 2017-11-16
CN105263933A (zh) 2016-01-20
TN2015000474A1 (en) 2017-04-06
CN105263933B (zh) 2017-12-22
RU2015149832A (ru) 2017-05-25
CA2909924A1 (fr) 2014-10-30
RU2660417C2 (ru) 2018-07-06
EP2989104A1 (fr) 2016-03-02

Similar Documents

Publication Publication Date Title
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MX393395B (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo.
MA38803A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
BR112014012056A8 (pt) compostos farmacêuticos
FR2986002A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
EA201100032A1 (ru) Соединения пиридина
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
BR112016003229A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EP2582676A4 (fr) Modulateurs allostériques positifs du récepteur m1 de l'amide tétrahydroquinoline
EA201200952A1 (ru) Производные пиразина и их применение для лечения неврологических нарушений
MX2013003635A (es) Compuestos de n-heteroarilo.
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EA201590697A1 (ru) Производные кетамина
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
TR201821157T4 (tr) İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m.
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
MX2015014905A (es) Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS